%0 Journal Article
%T Coronary Plaque in People With HIV vs Non-HIV Asymptomatic Community and Symptomatic Higher-Risk Populations.
%A Karady J
%A Lu MT
%A Bergström G
%A Mayrhofer T
%A Taron J
%A Foldyna B
%A Paradis K
%A McCallum S
%A Aberg JA
%A Currier JS
%A Fitch KV
%A Fulda ES
%A Bloomfield GS
%A Overton ET
%A Lind L
%A Östgren CJ
%A Elvstam O
%A Söderberg S
%A Jernberg T
%A Pepe R
%A Dubé MP
%A Mushatt D
%A Fichtenbaum CJ
%A Malvestutto C
%A Zanni MV
%A Hoffmann U
%A Ribaudo H
%A Grinspoon SK
%A Douglas PS
%J JACC Adv
%V 3
%N 6
%D 2024 Jun
%M 38938873
暂无%R 10.1016/j.jacadv.2024.100968
%X <B>UNASSIGNED: </B>People with HIV (PWH) have a high burden of coronary plaques; however, the comparison to people without known HIV (PwoH) needs clarification.<BR><B>UNASSIGNED: </B>The purpose of this study was to determine coronary plaque burden/phenotype in PWH vs PwoH.<BR><B>UNASSIGNED: </B>Nonstatin using participants from 3 contemporary populations without known coronary plaques with coronary CT were compared: the REPRIEVE (Randomized Trial to Prevent Vascular Events in HIV) studying PWH without cardiovascular symptoms at low-to-moderate risk (n = 755); the SCAPIS (Swedish Cardiopulmonary Bioimage Study) of asymptomatic community PwoH at low-to-intermediate cardiovascular risk (n = 23,558); and the PROMISE (Prospective Multicenter Imaging Study for Evaluation of Chest Pain) of stable chest pain PwoH (n = 2,291). The coronary plaque prevalence on coronary CT was compared, and comparisons were stratified by 10-year atherosclerotic cardiovascular disease (ASCVD) risk, age, and coronary artery calcium (CAC) presence.<BR><B>UNASSIGNED: </B>Compared to SCAPIS and PROMISE PwoH, REPRIEVE PWH were younger (50.8 ± 5.8 vs 57.3 ± 4.3 and 60.0 ± 8.0 years; P < 0.001) and had lower ASCVD risk (5.0% ± 3.2% vs 6.0% ± 5.3% and 13.5% ± 11.0%; P < 0.001). More PWH had plaque compared to the asymptomatic cohort (48.5% vs 40.3%; P < 0.001). When stratified by ASCVD risk, PWH had more plaque compared to SCAPIS and a similar prevalence of plaque compared to PROMISE. CAC = 0 was more prevalent in PWH (REPRIEVE 65.2%; SCAPIS 61.6%; PROMISE 49.6%); among CAC = 0, plaque was more prevalent in PWH compared to the PwoH cohorts (REPRIEVE 20.8%; SCAPIS 5.4%; PROMISE 12.3%, P < 0.001).<BR><B>UNASSIGNED: </B>Asymptomatic PWH in REPRIEVE had more plaque than asymptomatic PwoH in SCAPIS but had similar prevalence to a higher-risk stable chest pain cohort in PROMISE. In PWH, CAC = 0 does not reliably exclude plaque.